Publication:
Rituximab therapy for treatment of pemphigus in Southeast Asians

0
0

Issued Date

2021

Resource Type

Article

Language

eng

File Type

application/pdf

ISSN

11778881

DOI

10.2147/DDDT.S306046

Other identifier(s)

2-s2.0-85105024589

Rights Holder(s)

มหาวิทยาลัยศรีนครินทรวิโรฒ

Bibliographic Citation

Drug Design, Development and Therapy. Vol 15, No. (2021), p.1677-1690

Suggested Citation

Kanokrungsee S., Anuntrangsee T., Tankunakorn J., Srisuwanwattana P., Suchonwanit P., Chanprapaph K. Rituximab therapy for treatment of pemphigus in Southeast Asians. Drug Design, Development and Therapy. Vol 15, No. (2021), p.1677-1690. doi:10.2147/DDDT.S306046 Retrieved from: https://hdl.handle.net/20.500.14740/8056

Title

Rituximab therapy for treatment of pemphigus in Southeast Asians

Author(s)

Kanokrungsee S.
 Anuntrangsee T.
 Tankunakorn J.
 Srisuwanwattana P.
 Suchonwanit P.
 Chanprapaph K.

Abstract

Background: Rituximab provides more effective and less adverse effects than the standard dose of corticosteroids, but evidence on its efficacy and safety in the Thai population is lacking. Objective: To evaluate the efficacy and safety of rituximab in the treatment of pemphigus and also to determine prognostic factors linked to the treatment outcomes. Methods: Pemphigus patients who received rituximab from November 2017 to December 2020 were retrospectively reviewed. The outcome was evaluated by using early (end of consolidation phase [ECP]) and late endpoints (complete remission [CR] on/off therapy, immunological remission [IR], and relapse). Adverse events were noted. Prognostic factors associated with remission and relapse were analyzed. Results: Of 53 pemphigus patients, all attained ECP within 1.61 months. Almost 80% achieved CR on therapy within a median time of 6.36 months, while 33.9% reached CR off therapy in 19.74 months. Nearly half had IR within a median time of 6.88 months. Relapse occurred in 33.3% with a median time of 14 months. In multivariate analysis, receiving rituximab within 12 months of disease duration was more likely to achieve CR off therapy and IR (hazard ratio [HR] 3.79; 95% confidence interval [CI] 1.38, 10.42; P = 0.01 and HR 2.74; 95% CI 1.12, 6.69; P = 0.027, respectively), whereas older patients and positive anti-desmoglein 1 levels at the time of CR were predictive indicators for relapse (HR 1.07; 95% CI 1.01, 1.13; P = 0.036 and HR 4.38; 95% CI 1.24, 15.46; P = 0.022, respectively). The treatment-related adverse effects occurred in 33.9%. Conclusion: Rituximab is effective and safe in Thai pemphigus patients. Early administration of rituximab was a predictor of clinical and immunological remission. Older age and persistently positive anti-Dsg1 were correlated with disease relapse. © 2021 Kanokrungsee et al.

Subject(s)

Desmoglein 1 antibody
 Rituximab
 Rituximab
 Adult
 Aging
 Article
 Cohort analysis
 Disease duration
 Drug efficacy
 Drug safety
 Early intervention
 Female
 Human
 Major clinical study
 Male
 Middle aged
 Multiple cycle treatment
 Pemphigus
 Predictive value
 Prognosis
 Recurrent disease
 Remission
 Retrospective study
 Southeast Asian
 Thai (citizen)
 Treatment outcome
 Adolescent
 Aged
 Asian continental ancestry group
 Pemphigus
 Young adult
 Adolescent
 Adult
 Aged
 Asian Continental Ancestry Group
 Cohort Studies
 Female
 Humans
 Male
 Middle Aged
 Pemphigus
 Retrospective Studies
 Rituximab
 Young Adult

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/8056

Collections

Scopus: Year 1983-2021

Endorsement

Review

Supplemented By

Referenced By